Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Speciality European Pharma
Speciality European Pharma
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Plenaxis
Abarelix
2003-11-25
—
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Abarelix
prostatic neoplasms
,
endometriosis
Aglatimagene besadenovec
lymphoma
,
triple negative breast neoplasms
,
pharmacokinetics
,
healthy volunteers/patients
,
pharmacological phenomena
,
neoplasms
,
breast neoplasms
,
adenocarcinoma
,
neoplasm metastasis
,
carcinoma
,
ovarian neoplasms
,
non-small-cell lung carcinoma
,
pancreatic neoplasms
,
colorectal neoplasms
,
lung neoplasms
,
uterine cervical neoplasms
,
endometrial neoplasms
,
stomach neoplasms
,
urinary bladder neoplasms
,
small cell lung carcinoma
,
biliary tract neoplasms
,
bone neoplasms
,
bone diseases
,
hereditary breast and ovarian cancer syndrome
,
aggression
,
head and neck neoplasms
,
dna repair-deficiency disorders
,
sarcoma
,
ovarian epithelial carcinoma
,
recurrence
,
hypersensitivity
,
gynecomastia
,
prostatic neoplasms
,
castration-resistant prostatic neoplasms
,
heart failure
,
coronary disease
,
coronary artery disease
,
myocardial ischemia
,
heart diseases
,
osteoporosis
,
obesity
,
disease susceptibility
,
hepatocellular carcinoma
,
liver neoplasms
Nepidermin
gastroesophageal reflux
,
peptic esophagitis
,
heartburn
,
liver diseases
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use